Jun Yao Health (605388): Q3 revenue is under short-term pressure, gross margin improved markedly
Jun Yao Health (605388): Probiotic foods lead the growth rate, repurchases show confidence in development
Jun Yao Health (605388): Runying and Panyuan supply chains increase revenue and expect continuous improvement
Jun Yao Health (605388): Profit-side improvements have clearly shown results in overseas expansion
Jun Yao Health (605388): Steady growth on the revenue side focuses on Runying's order execution
Jun Yao Health (605388): Continuing to improve the health layout after starting a second business
Junyao Health (605388): Successful integration of Runying Probiotics can be expected on the second curve
Junyao Health (605388): Performance is in line with expectations, focus on new product performance
Jun Yao Health (605388): 2022 ended smoothly and 2023 accelerated recovery
Junyao Health (605388): Reorganizing Runying Biotech's Industrial Chain Layout
Junyao Health (605388): Channel adjustment Xu Li short-term performance under pressure
Jun Yao Health (605388) Research Briefing: The main business is expected to pick up and actively explore the second growth curve
Junyao Health (605388): the first unit of lactic acid bacteria waiting for a reversal of performance
Junyao Health (605388): room temperature lactobacillus beverage bibcock to help speed up the development
Offline inquiry strategy for new shares of Junyao Health (605388)
Junyao Health (605388) IPO inquiry report
New shares offline application inquiry proposal report: Junyao Health (605388)
No Data
No Data